A handful of announcements this morning from AIM-listed food supplement specialist Provexis (LON: PXS) saw its shares nudge up 5.5 percent to 3.11 pence by 9:00 am.
The firm – which focuses on the discovery, development and licensing of technologies for the functional food, dietary supplement and medical food sectors – said that it is expanding its NSP-3G human trial aimed at maintaining remission in Crohn’s disease patients.
Following an independent review by the Data Monitoring Committee, which confirmed there are no negative findings associated with data gathered from the first patients to complete 12 months of treatment, Provexis plans to identify up to four additional trial centres to facilitate recruitment of the remaining patients it requires in order to complete the trial quickly.
Provexis also announced that DSM Nutritional Products has now entered into an agreement to commercialise DSM-owned intellectual property through the development of a new product for the promotion of healthy blood glucose levels.
“In recent months we have assessed the technology and believe that it will further strengthen our pipeline of cardiovascular-related technologies,” said Stephen Moon, Provexis’s CEO. “The collaborative approach facilitated by the agreement will allow for the most effective commercialisation of the technology. In addition to this important new pipeline technology, the management team continues to assess further potential acquisitions."
Meanwhile, the firm announced it had appointed a new product director. It said Luke Heeney, previously innovation director at Findus Group, has been appointed specifically to manage the process of commercialising the company’s IP from the development phase through to final product.